Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19

NCT04411433 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

1008

Enrollment

OTHER_GOV

Sponsor class

Conditions

Sars-CoV2
COVID-19

Interventions

DRUG: Favipiravir (3200 mg + 1200 mg)
DRUG: Favipiravir (3600 mg + 1600 mg)
DRUG: Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine
DRUG: Favipiravir (3200 mg + 1200 mg) combined with Azithromycin
DRUG: Hydroxychloroquine
DRUG: Hydroxychloroquine combined with Azithromycin

Sponsor

Ministry of Health, Turkey

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]